You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Multiple Myeloma 

  • Authors: Session chair: Shaji Kumar, MD; Faculty: Anita D'Souza, MD; Charise Gleason, MSN, NP-C, AOCNP; Nisha Joseph, MD; Amrita Krishnan, MD, FACP; Sagar Lonial, MD, FACP; Kathryn Maples, PharmD, BCOP; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MSc
  • CME / ABIM MOC / CE Released: 10/11/2022
  • Valid for credit through: 10/11/2023
Start Activity

  • Credits Available

    Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 2.50 ABIM MOC points

    Nurses - 2.50 ANCC Contact Hour(s) (2.25 contact hours are in the area of pharmacology)

    Pharmacists - 2.50 Knowledge-based ACPE (0.250 CEUs)

    IPCE - 2.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is that learners will be better able to personalize treatment for patients with multiple myeloma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data on treatment strategies for multiple myeloma
  • Have greater competence related to
    • Selecting evidence-based treatment for patients with newly diagnosed or relapsed/refractory multiple myeloma
    • Managing adverse events associated with current therapies for patients with multiple myeloma
  • Demonstrate greater confidence in their ability to
    • Personalize treatment for patients with multiple myeloma in an interprofessional team-based environment

 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Session chair

  • Shaji Kumar, MD

    Professor of Medicine
    Division of Hematology
    Department of Internal Medicine
    Mayo Clinic
    Rochester, Minnesota

    Disclosures

    Shaji Kumar, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; Antengene; ArcellX; AstraZeneca; BeiGene; Bluebird; Bristol Myers Squibb Company; Epizyme; Genentech; Janssen; K36 Therapeutics; Loxo; Monterosa; Oncopeptides; Roche; Sanofi; SecuraBio; Trillium
    Research funding from: AbbVie; Amgen; Allogene; AstraZeneca; Bristol Myers Squibb Company; Carsgen; Genentech; GlaxoSmithKline; Janssen; Molecular Templates; Novartis; Regeneron; Roche; Takeda

Faculty

  • Nisha Joseph, MD

    Assistant Professor
    Department of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Joseph and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Joseph’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Nisha Joseph, MD, has no relevant financial relationships.

  • Ajay Nooka, MD, MPH, FACP

    Associate Professor
    Department of Hematology and Medical Oncology
    Medical Director
    Winship Data and Technology Applications Shared Resource
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Nooka and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Nooka’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Ajay Nooka, MD, MPH, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Adaptive; Amgen; Beyond Springs; Bristol Myers Squibb Company; GlaxoSmithKline; Karyopharm; Legend; Oncopeptides; Sanofi; SecuraBio; Takeda
    Research funding from: Amgen; Arch; Bristol Myers Squibb Company; Genentech; GlaxoSmithKline; Janssen; Karyopharm; Kite; Takeda

  • Amrita Krishnan, MD, FACP

    Director
    Judy and Bernard Briskin Center for Multiple Myeloma Research
    Professor
    Department of Hematology and Hematopoietic Cell Transplantation
    City of Hope Medical Center
    Duarte, California

    Disclosures

    Amrita Krishnan, MD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Adaptive; Artiva; AstraZeneca; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Pfizer; Regeneron; Sanofi
    Speaker or member of speakers bureau for: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Takeda
    Research funding from: Janssen
    Ownership interest: Bristol Myers Squibb Company
    Other: Scientific advisory board for: SUTRO

  • Krina Patel, MD, MSc

    Associate Professor
    Center Medical Director
    Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Krina Patel, MD, MSc, has the following relevant financial relationships:
    Consultant or advisor for: ArcellX; Bristol Myers Squibb Company; Celgene; Cellectis; Janssen; Karyopharm; Oncopeptides; Pfizer
    Contracted researcher for: Allogene; Bristol Myers Squibb Company; Celgene; Cellectis; Nektar; Precision; Takeda

  • Sagar Lonial, MD, FACP

    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Lonial’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Sagar Lonial, MD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; Bristol Myers Squibb Company; Celgene; Cellectis; GlaxoSmithKline; Janssen; Novartis; Takeda
    Research funding from: CR Therapeutics; Janssen; Novartis; Takeda
    Owns stock (publicly traded) in: TG Therapeutics
    Other: Board of directors for: TG Therapeutics

  • Anita D'Souza, MD

    Associate Professor of Medicine
    Division of Hematology/Oncology
    Medical College of Wisconsin
    Milwaukee, Wisconsin

    Disclosures

    Anita D'Souza, MD, has the following relevant financial relationships:
    Consultant or advisor for: Arivan; Bristol Myers Squibb Company; Eradigm; Janssen; Prothena
    Research funding from: AbbVie; Caelum; Janssen; Novartis; Prothena; Regeneron; Sanofi; TeneoBio

  • Charise Gleason, MSN, NP-C, AOCNP

    Adjunct Faculty
    Nell Hodgson Woodruff School of Nursing
    Advanced Practice Provider Chief
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Gleason and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Gleason’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships.

  • Kathryn Maples, PharmD, BCOP

    Clinical Pharmacy Specialist
    Emory Healthcare
    Atlanta, Georgia

    Disclosures

    ​The opinions expressed are those of Dr Maples and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Maples’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Kathryn Maples, PharmD, BCOP, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Janssen; Sanofi

Editor

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC

    Disclosures

    ​Megan Whitney, DMD, has no relevant financial relationships. 

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships. 

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships. 

Peer Reviewer:

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 2.50 contact hour(s) (0.250 CEUs) (Universal Activity Number: JA0007105-0000-22-360-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Multiple Myeloma 

Authors: Session chair: Shaji Kumar, MD; Faculty: Anita D'Souza, MD; Charise Gleason, MSN, NP-C, AOCNP; Nisha Joseph, MD; Amrita Krishnan, MD, FACP; Sagar Lonial, MD, FACP; Kathryn Maples, PharmD, BCOP; Ajay Nooka, MD, MPH, FACP; Krina Patel, MD, MScFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/11/2022

Valid for credit through: 10/11/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Smoldering Myeloma Debate: To Treat or Not to Treat

Would you observe or treat a patient with smoldering myeloma? What is the rationale for each approach?
Shaji Kumar, MD; Nisha Joseph, MD

Advances in the Treatment of Newly Diagnosed Multiple Myeloma

Are there new treatment approaches for patients with newly diagnosed multiple myeloma?
Ajay Nooka, MD, MPH, FACP

Approaches to Maintenance Therapy in Multiple Myeloma

What is the latest data in maintenance therapy?
Amrita Krishnan, MD, FACP

Keys to Response Assessment in Multiple Myeloma

What is the role of response assessment in managing a patient with multiple myeloma?
Shaji Kumar, MD

Management of Early Relapsed/Refractory Multiple Myeloma

What are the latest advances in treatment for early relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP

Evolving Treatment Strategies in Late Relapsed/Refractory Multiple Myeloma

How do you choose among the many treatment options for late relapsed/refractory multiple myeloma?
Krina Patel, MD, MSc

Supportive Care Considerations for Patients With Multiple Myeloma

How do you manage symptom burden and help improve quality of life in patients with multiple myeloma?
Anita D'Souza, MD

Interprofessional Myeloma Management: A Case-Based Discussion

Watch experts across the professions discuss the team approach to caring for patients with multiple myeloma.
Shaji Kumar, MD; Charise Gleason, MSN, NP-C, AOCNP; Kathryn Maples, PharmD, BCOP
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to personalize treatment for patients with multiple myeloma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.